

080406

15866

U.S. PTO

8-7-06

10/588555

IAP7 Rec'd PCT/PTO 04 AUG 2006

Pct\$

Attorney Docket No.: 10517.204-US

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE  
(DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This is a request for filing a patent application under 35 U.S.C. 371 of the international application identified below:

INTERNATIONAL APPLICATION NO. PCT/DK2005/000097		INTERNATIONAL FILING DATE February 14, 2005	
APPLICANT(S)/INVENTOR(S)			
First Name	Middle Name	Family Name	
1.Allan 2.Stefan 3.	1. 2. 3.	1.Svensden 2.Minning 3.	
TITLE OF THE INVENTION			
Protease Variants			

1. This is a first submission of items concerning a filing under 35 U.S.C. 371.
2. This is an express request to begin national examination procedures (35 U.S.C. 371(f)).
3. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) has been communicated by the International Bureau. The application contains the following parts:

Specification	95 Pages
Abstract	1 Pages
Sequence Listing	28 Pages
Drawings	4 Pages
Total	128 Pages

4. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) have not been made and will not be made.
5. An application data sheet is enclosed.
6. Priority of Danish application no. PA 2004 00226 filed on February 13, 2004 is claimed under 35 U.S.C. 119(a)-(d).

7. The benefit of U.S. provisional application no. 60/558,191 filed on March 31, 2004 is claimed under 35 U.S.C. 119(e).
8. An oath or declaration of the inventors is submitted herewith.
9. An Information Disclosure Statement is submitted herewith.
10. A Preliminary Amendment is submitted herewith.
11. Applicants enclose a paper copy and a computer readable form of a Sequence Listing. The content of the paper copy and of the computer readable form is the same.
12. The assignee of the present application is:

Novozymes A/S  
Krogshoejvej 36  
DK-2880 Bagsvaerd  
Denmark

Applicants request that the assignee information be included in the published patent application.

13. Direct all correspondence to Customer Number 25908.
14. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):

Basic Fee:	\$300.00
Examination Fee:	\$200.00
Search Fee:	\$500.00
Size Fee (\$250 for each 50 pages above 100)	\$0.00

CLAIMS FEE


Total Claims: 15 - 20 = 0 x 50 =	\$0.00
Independent Claims: 1 - 3 = 0 x 200 =	\$0.00
Total Claims Fee:	\$0.00

TOTAL NATIONAL FEE	\$1,000.00
--------------------	------------

15. Please charge the required fee, estimated to be \$1,000, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: August 4, 2006

  
\_\_\_\_\_  
Elias J. Lambiris, Reg. No. 33,728  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097

10/588555  
IAP11 Rec'd PCT/PTO 04 AUG 2006

Attorney Docket No. 10517.204-US

PATENT

**IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)**

INTERNATIONAL APPLICATION NO.: PCT/DK2005/000097

INTERNATIONAL FILING DATE: February 14, 2005

PRIORITY DATE: February 13, 2004

TITLE: Protease Variants

APPLICANT(S) FOR RO/US: Svendsen et al

**EXPRESS MAIL CERTIFICATE**

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Express Mail Label No. EV 611573902 US

Date of Deposit: August 4, 2006

I hereby certify that the following attached papers or fee

1. Transmittal Letter to the DO/EO/US (in duplicate)
2. Executed Combined Declaration and Power of Attorney
3. Application Data Sheet
4. Preliminary Amendment
5. Paper Copy of Sequence Listing
6. Disk Containing Sequence Listing
7. Information Disclosure Statement
8. Form PTO/SB/08A
9. Copy of References

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the address indicated above.

Julie Tabarovsky

(Name of person mailing paper(s) or fee)

Julie Tabarovsky

(Signature of person mailing paper(s) or fee)

Mailing Address:

Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097